Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted significant challenges, including a 36.2% revenue decline, increased SG&A expenses, and a net loss, indicating financial strain. Despite optimistic guidance on coach productivity and new programs, economic uncertainties and competition pose risks. The Q&A session revealed unclear management responses, adding to investor concerns. Although there are plans for product evolution and a focus on metabolic health, the lack of immediate positive catalysts and the absence of a market cap suggest a negative stock price movement in the short term.
Key Financial Performance
Revenue $89.4 million, a decrease of 36.2% year-over-year, primarily due to a decrease in the number of active earning OPTAVIA coaches.
Active Earning OPTAVIA Coaches Approximately 19,500, a decrease of 35% from the third quarter of 2024, attributed to challenges in client acquisition.
Average Revenue per Active Earning OPTAVIA Coach $4,585, a year-over-year decrease of 1.9%, primarily driven by continued pressure on client acquisition.
Gross Profit $62.2 million, a decrease of 41.2% year-over-year, driven by lower sales volumes, partially offset by lower cost of sales.
Gross Profit Margin 69.5%, a decrease of 590 basis points compared to the year earlier period, due to 450 basis points of loss of leverage on fixed costs and 180 basis points of a reserve for the reformulation of the Essential product line.
SG&A Expense $66.2 million, down 36% year-over-year, primarily due to a $19.7 million decrease in coach compensation on fewer active earning coaches and lower volumes, along with reductions in marketing and convention costs.
Loss from Operations $4.1 million, compared to income from operations of $2.1 million in the prior year period, reflecting a shift to a loss of 4.6% of revenue from a prior income of 1.5%.
Net Loss $2.3 million or $0.21 loss per diluted share, compared to net income of $1.1 million or $0.10 per share in the year-earlier period.
Cash, Cash Equivalents, and Investments $173.5 million, with no interest-bearing debt as of September 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Line: Medifast plans to launch a new product line next year using the science of metabolic synchronization and next-generation ingredients for metabolic enhancement. This product line aims to improve upon the current Essential product line and address overall metabolic health.
Clinical Research Findings: Recent clinical analysis revealed that Medifast's comprehensive plan delivers strong fat burn, retains 98% of lean mass, reduces visceral fat by 14%, and improves body composition over 16 weeks.
Market Positioning Shift: Medifast is transitioning from being seen as a weight loss company to a leader in metabolic health, targeting a larger and more durable market.
Coach Training and Development: Coach leaders have been trained on new clinical data, and training will continue into 2026 to help coaches reach clients focused on metabolic health.
Digital Platform Enhancements: Investments in digital platforms, including app and reporting tool enhancements, aim to improve client progress visibility and coach performance.
Premier+ Pricing and Auto Ship Program: This program simplifies the value proposition, offering savings, predictable pricing, and improved client retention.
EDGE Leadership Development Program: The program supports coach growth through incentives, best practices, and recognition tools, enhancing coach productivity and stability.
Strategic Focus on Metabolic Health: Medifast is focusing on long-term metabolic health solutions, combining clinical credibility, human connection, and healthy results.
Financial Position: The company has $173.5 million in cash and no debt, providing a strong foundation for future growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue for the third quarter decreased by 36.2% year-over-year, primarily due to a decrease in the number of active earning OPTAVIA coaches.
Coach Attrition: The number of active earning OPTAVIA coaches decreased by 35% compared to the third quarter of 2024, impacting client acquisition and overall revenue.
Client Acquisition Pressure: Continued pressure on client acquisition contributed to a 1.9% year-over-year decrease in average revenue per active earning coach.
Gross Profit Decline: Gross profit decreased by 41.2% year-over-year due to lower sales volumes and a reserve for reformulation of the Essential product line.
SG&A Expense Challenges: SG&A expenses as a percentage of revenue increased due to loss of leverage on fixed costs, despite reductions in marketing and convention costs.
Operational Loss: The company reported a loss from operations of $4.1 million in the third quarter, compared to income from operations of $2.1 million in the prior year period.
Net Loss: Net loss for the third quarter was $2.3 million, compared to net income of $1.1 million in the prior year period.
Product Transition Risk: The planned replacement of the Essential product line with a new product line in 2026 introduces risks related to product acceptance and transition.
Market Competition: The rise of GLP-1 medications poses a competitive challenge, as these medications are reshaping the weight loss and wellness industry.
Economic Uncertainty: The company faces broader economic uncertainties that could impact consumer spending and demand for its products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q4 2025: Expected revenue to range from $65 million to $80 million.
Earnings Guidance for Q4 2025: Anticipated loss per share ranging from $0.70 to $1.25.
Product Launch Plans: The company plans to launch a new product line in 2026, focusing on metabolic synchronization and next-generation ingredients for metabolic enhancement.
Coach Training and Expansion: Training for coaches on new clinical data and reaching new client types will continue into 2026.
Digital Platform Enhancements: Investments in digital platforms to improve coaching and client experience will continue.
Market Positioning: The company is shifting focus from weight loss to broader metabolic health, targeting a larger and more durable market.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company integrating the focus on metabolic dysfunction with coach training?
A:The company is conducting a study tied to previous research and clinical studies to show how their program addresses metabolic health and reverses metabolic dysfunction. They are training leaders and coaches through retreats and ongoing sessions to ensure consistent messaging. By the end of the year, all coaches are expected to be trained on the new direction.
Q:What is the EDGE program and its incentive structure?
A:The EDGE program focuses on creating, duplicating, and multiplying Executive Directors, who generate approximately $6,000 in revenue each. The program aims to improve rank composition, increase productivity, and enhance revenue. Training and execution of the program were discussed at the Sundance leadership retreat.
Q:How should we think about the alignment between SG&A expenses and top-line performance?
A:The company incurred a $1.5 million one-time charge for reformulating its essential line in Q3. They are rightsizing the business to improve margins as they return to growth. They expect stabilization in revenue per active earning coach in Q4 or within the next six months, which will lead to coach and revenue growth.
Q:How is broader economic softness impacting consumer spending on the company's program?
A:While economic challenges affect consumer spending, the company observes that consumers prioritize health. They see high satisfaction and repeat rates among clients. The program is positioned as valuable and relevant, especially for those using or transitioning off GLP-1 drugs.
Q:What is the status of the LifeMD collaboration and its impact on SG&A expenses?
A:The collaboration with LifeMD is ongoing. The $2 million amortization in Q3 2024 was the last of a $10 million investment, so this expense will no longer appear in SG&A going forward.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear formula or specific guidance on how SG&A expenses would align with top-line performance in the future, offering only general statements about rightsizing and expected stabilization.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Coach understanding
Coaching difference
Conference Instructions
EDGE component
EDGE development
EDGE incentive
Enhancements app
Premier EDGE
body composition
connection
cycle
fat mass
field
foundation
generation
health term
industry
loss metabolic
market
metabolic dysfunction
metabolic health
metabolic synchronization
million people
opportunity front
people metabolic
pricing
process
reset
science coach
science metabolic
stability
system people
work
world
MED Transcript
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Unknown5-4
The earnings call revealed a significant decline in key financial metrics: revenue, net income, EPS, and cash flow from operations all decreased year-over-year. Additionally, gross profit margin fell, and operating expenses rose. These factors indicate financial challenges and increased costs, leading to a negative sentiment. The absence of strategic initiatives, risk assessment, and return discussions further weakens investor confidence, suggesting a likely negative stock price movement in the short term.
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Unknown2-17
The earnings call revealed substantial challenges: a 36.9% revenue decline, a 40.6% drop in active coaches, and a net loss of $18.1 million. Despite some positive aspects like improved coach productivity and a focus on metabolic health, the lack of guidance on revenue stabilization and ongoing losses indicate financial strain. The restructuring efforts and regulatory risks add further uncertainty. The Q&A section highlighted management's vague responses, negatively impacting sentiment. These factors suggest a negative stock price reaction over the next two weeks.
Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call highlighted significant challenges, including a 36.2% revenue decline, increased SG&A expenses, and a net loss, indicating financial strain. Despite optimistic guidance on coach productivity and new programs, economic uncertainties and competition pose risks. The Q&A session revealed unclear management responses, adding to investor concerns. Although there are plans for product evolution and a focus on metabolic health, the lack of immediate positive catalysts and the absence of a market cap suggest a negative stock price movement in the short term.
Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript
Unknown8-4
The earnings call revealed significant challenges: a 37.4% revenue decline, reduced coach productivity, and client acquisition pressures. Despite cost optimizations and no debt, the market faces economic uncertainties and competitive challenges from GLP-1 medications. Q&A insights did not mitigate these concerns, as reliance on GLP-1 was noted. While operational improvements and investment gains led to positive net income, the weak revenue guidance and coach network issues indicate a negative short-term outlook, likely resulting in a stock price decline of -2% to -8%.
MED Slides
MED Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
